Abstract
In this review, we discuss the role of cell cycle dysfunction in the pathogenesis of Alzheimer disease and propose that such mitotic catastrophe, as one of the earliest events in neuronal degeneration, may, in fact, be sufficient to initiate the neurodegenerative cascade. The question as to what molecule initiates cell cycle dysfunction is now beginning to become understood and, in this regard, the gender-predication, age-related penetrance and regional susceptibility of specific neuronal populations led us to consider luteinizing hormone as a key mediator of the abnormal mitotic process. As such, agents targeted toward luteinizing hormone or downstream sequelae may be of great therapeutic value in the treatment of Alzheimer disease.
Keywords: alzheimer disease, amyloid, cell cycle, leuprolide acetate, luteinizing hormone, oxidative stress, tau phosphorylation
Current Drug Targets
Title: Mitotic and Gender Parallels in Alzheimer Disease: Therapeutic Opportunities
Volume: 5 Issue: 6
Author(s): X. Zhu, K. M. Webber, G. Casadesus, A. K. Raina, H. G. Lee, M. Marlatt, A. Hartzler, C. S. Atwood, R. Bowen, G. Perry and M. A. Smith
Affiliation:
Keywords: alzheimer disease, amyloid, cell cycle, leuprolide acetate, luteinizing hormone, oxidative stress, tau phosphorylation
Abstract: In this review, we discuss the role of cell cycle dysfunction in the pathogenesis of Alzheimer disease and propose that such mitotic catastrophe, as one of the earliest events in neuronal degeneration, may, in fact, be sufficient to initiate the neurodegenerative cascade. The question as to what molecule initiates cell cycle dysfunction is now beginning to become understood and, in this regard, the gender-predication, age-related penetrance and regional susceptibility of specific neuronal populations led us to consider luteinizing hormone as a key mediator of the abnormal mitotic process. As such, agents targeted toward luteinizing hormone or downstream sequelae may be of great therapeutic value in the treatment of Alzheimer disease.
Export Options
About this article
Cite this article as:
Zhu X., Webber M. K., Casadesus G., Raina K. A., Lee G. H., Marlatt M., Hartzler A., Atwood S. C., Bowen R., Perry G. and Smith A. M., Mitotic and Gender Parallels in Alzheimer Disease: Therapeutic Opportunities, Current Drug Targets 2004; 5 (6) . https://dx.doi.org/10.2174/1389450043345317
DOI https://dx.doi.org/10.2174/1389450043345317 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Neuronal Insulin/Insulin-Like Growth Factor-1 Signaling for the Pathogenesis of Alzheimer’s Disease: Possible Therapeutic Implications
CNS & Neurological Disorders - Drug Targets The Pharmacokinetics and Toxicology of Aluminum in the Brain
Current Inorganic Chemistry (Discontinued) Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways
Current Neuropharmacology Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System
Current Pharmaceutical Design Pharmaceutical Interventions for Frailty and Sarcopenia
Current Pharmaceutical Design Computational Investigation on Tyrosine to Alanine Mutations Delaying the Early Stage of α-Synuclein Aggregation
Current Proteomics Marking the Centennial of Alzheimers First Report of the Disease with a Perspective of Ongoing Research and Future Challenge
Current Alzheimer Research The Effects of Olprinone, a Phosphodiesterase 3 Inhibitor, on Systemic and Cerebral Circulation
Current Vascular Pharmacology A Computational Approach to Finding RNA Tertiary Motifs in Genomic Sequences: A Case Study
Recent Patents on DNA & Gene Sequences Neuroprotective Effects of Lutein in the Retina
Current Pharmaceutical Design The Immune Protective Effect of the Mediterranean Diet against Chronic Low-grade Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Early Prediction of Preeclampsia: Hope for Early Intervention?
Current Women`s Health Reviews Mental Training for Cognitive Improvement in Elderly People: What have We Learned from Clinical and Neurophysiologic Studies?
Current Alzheimer Research Editorial [Hot Topic New Clinical Indications of Antipsychotic Medications Guest Editors: Filippo Bogetto and Silvio Bellino]
Current Psychopharmacology Are Retinoids a Promise for Alzheimer’s Disease Management?
Current Medicinal Chemistry Concurrent Use of Antiretrovirals and Anticonvulsants in Human Immunodeficiency Virus (HIV) Seropositive Patients
Current Pharmaceutical Design Therapeutic Perspectives in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Area, Age and Gender Dependence of the Nucleoside System in the Brain: a Review of Current Literature
Current Topics in Medicinal Chemistry A Dual Activity of ROS and Oxidative Stress on Adult Neurogenesis and Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Perioperative Handling of Antiplatelet Drugs. A Critical Appraisal
Current Drug Targets